secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001682852-24-000043
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B
--------------------------------------------------------------------------------

- Revenue $241M vs $344M YoY; net product sales $184M (-37%).
- Revised FY2024 product sales guidance to $3.0-3.5B; cites low EU sales, deferrals, competitive US market.
- RSV vaccine mRESVIA approved by FDA, shipping since July; EMA positive opinion.
- Phase 3 data positive for combo flu+COVID and next-gen COVID vaccines; filings planned in 2024.
- David Rubenstein joins Board Aug 5; Robert Langer and Stephen Berenson retire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000043/0001682852-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000043/mrna-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001682852-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer